Wilson's Disease Treated With D-Penicillamine: Characterization of Skin Damage Secondary to Treatment by Measuring Skin Elasticity (WILDERME)

Centre Hospitalier Universitaire de Saint Etienne

Status: Begins enrollment this month

Conditions: Wilson Disease; D-Penicillamine

Treatments: Other: Preparation of forearm molds with SILFLO® silicone

Study type: Interventional

Funder types: Other

Identifiers

NCT06945081

25CH057

ANSM (Other Identifier)

Details and patient eligibility

About

Wilson's disease is a genetic disorder, resulting from an anomaly present on the ATP7B gene located on chromosome 13, causing a progressive accumulation of copper in various organs such as the liver, nervous system and cornea, leading to various hepatic and neurological disorders and a systemic evolution.

Currently, the first-line treatment for this disease is D-Penicillamine, which acts by chelation and promotes copper excretion through the urine. Unfortunately, this treatment also has significant side-effects, particularly on the skin. However, the pathogenesis of elastopathy in patients with Wilson's disease has yet to be fully characterized, and needs to be better understood in order to adapt the therapeutic strategy.

A silicon mold will be made on Wilson's disease patients, enabling the skin micro-relief to be shaped, and analyzed by confocal laser in comparison with the skin of healthy volunteers.

Enrollment: 120 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Diseased patients :

• Patient over 12 years old
• Patient with Wilson's disease confirmed by genetic analysis
• Patient followed up in the Wilson's Disease Reference Center for his care
• Patient treated with D-Penicillamine
• Patient with no other known elastic tissue pathology

Healthy volunteers :

• Patient over 12 years old
• Patient followed up in the dermatology department of St Etienne University Hospital
• Patient matched on sex and age with a patient from the "Wilson's disease" group
• Patient with no elastic tissue pathology

All patients :

• Patient affiliated to a national social security
• Patient with written informed consent

Exclusion criteria

All patients:

• Patient not taking a treatment (at investigator's discretion) that may modify skin elasticity
• Patient with pathological lesion(s) on forearm or cheek
• Patient with a potentially active/rejuvenative forearm or cheek treatment
• Patient having applied cream and/or make-up to the areas to be molded (forearm and cheek)
• Patient under guardianship
• Patient unable to follow study procedures
• Pregnant or breast-feeding women

Trial design

Primary purpose: Supportive Care

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

120 participants in 2 patient groups

D-penicillamine

Experimental group

Description:

Patients with Wilson's disease treated with D-penicillamine for various exposure times

Treatment:

Other: Preparation of forearm molds with SILFLO® silicone

Healthy patients

Active Comparator group

Description:

Patients not diagnosed with wilson's disease and not receiving treatment that may affect skin elasticity

Treatment:

Other: Preparation of forearm molds with SILFLO® silicone